INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 281 filers reported holding INTRA CELLULAR THERAPIES INC in Q4 2022. The put-call ratio across all filers is 0.83 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $296,163 | -46.1% | 6,365 | -70.3% | 0.00% | -66.7% |
| Q2 2020 | $549,000 | -34.2% | 21,400 | -60.5% | 0.01% | -33.3% |
| Q1 2020 | $834,000 | -99.7% | 54,199 | -99.2% | 0.01% | -99.5% |
| Q4 2019 | $241,225,000 | +7767.7% | 7,030,748 | +1612.7% | 1.87% | +8021.7% |
| Q3 2019 | $3,066,000 | +239.9% | 410,499 | +490.5% | 0.02% | +228.6% |
| Q2 2019 | $902,000 | -85.4% | 69,512 | -82.3% | 0.01% | -83.3% |
| Q3 2017 | $6,183,000 | – | 391,792 | – | 0.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TANG CAPITAL MANAGEMENT LLC | 700,000 | $42,833,000 | 8.57% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 308,819 | $18,897,000 | 7.82% |
| Vahanian & Associates Financial Planning Inc. | 45,533 | $2,786,000 | 6.44% |
| DCF Advisers, LLC | 238,500 | $14,594,000 | 6.39% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 50,956 | $20,930,000 | 4.72% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,531,923 | $93,738,000 | 2.86% |
| Nicholas Investment Partners, LP | 562,373 | $34,412,000 | 2.45% |
| Bellevue Group AG | 3,429,619 | $209,859,000 | 2.44% |
| WASATCH ADVISORS LP | 7,477,868 | $457,571,000 | 2.25% |
| Quantum Private Wealth, LLC | 73,772 | $4,514,000 | 1.95% |